Revisiting thalidomide: Fighting with caution against idiopathic pulmonary fibrosis

Drugs of Today

Volumn 48, Issue 10, 2012, Pages 661-671

  Horton, Maureen R ^a   Hallowell, R W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenic; Idiopathic pulmonary fibrosis; Thalidomide; Vascular endothelial growth factor

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; CASPASE 9; CORTICOSTEROID; DEXAMETHASONE; DICKKOPF 1 PROTEIN; ETANERCEPT; FAS ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIRFENIDONE; PLACEBO; PROTEIN BAD; PROTEIN BAX; PROTEIN KINASE B; STAT1 PROTEIN; STEROID; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; APHTHOUS ULCER; APOPTOSIS; BEHCET DISEASE; BIRTH DEFECT; CANCER REGRESSION; CHRONIC COUGH; CONSTIPATION; CROHN DISEASE; CYTOKINE PRODUCTION; DISCOID LUPUS ERYTHEMATOSUS; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; EAR AGENESIS; EAR MALFORMATION; ERYTHEMA NODOSUM LEPROSUM; FIBROBLAST; FIBROSING ALVEOLITIS; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HEADACHE; HEARING IMPAIRMENT; HODGKIN DISEASE; HUMAN; IMMUNOMODULATION; INTERSTITIAL PNEUMONIA; KAPOSI SARCOMA; KIDNEY CARCINOMA; LANGERHANS CELL HISTIOCYTOSIS; LIBIDO DISORDER; LOEFFLER PNEUMONIA; LUNG SARCOIDOSIS; MOOD CHANGE; MORNING SICKNESS; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAIL DISEASE; NAUSEA; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOCOMELIA; PROSTATE CANCER; PULMONARY HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEDATION; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; TH1 CELL; TH2 CELL; TOXICITY TESTING; TREATMENT OUTCOME; TREMOR; VEIN THROMBOSIS;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; THALIDOMIDE;

EID: 84869232678     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.10.1855760     Document Type: Review

References (131)

1. Taussig, H.B. The thalidomide syndrome. Sci Am 1962, 207: 29-35.
2. Singhal, S., Mehta, J., Desikan, R. et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341(21): 1565-71.
3. Raza, A., Meyer, P., Dutt, D. et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98(4): 958-65.
4. Eisen, T., Boshoff, C., Mak, I. et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82(4): 812-7. (Pubitemid 30085231)
5. Fine, H.A., Figg, W.D., Jaeckle, K. et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000, 18(4): 708-15. (Pubitemid 30106600)
6. Figg, W.D., Dahut, W., Duray, P. et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001, 7(7): 1888-93. (Pubitemid 32994822)
7. Silverman, W.A. The schizophrenic career of a "monster drug". Pediatrics 2002, 110(2, Pt. 1): 404-6.
8. Moghe, V., Kulkarni, U., Parmar, U. Thalidomide. Bombay Hospital Journal 2008, 50(3): 472-6.
9. Dally, A. Thalidomide: was the tragedy preventable? Lancet 1998, 351(9110): 1197-9. (Pubitemid 28171835)
10. Ito, T., Ando, H., Suzuki, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327(5971): 1345-50.
11. Burkholz, H., Giving thalidomide a second chance, in FDA Consumer. 1997, U.S. Government Printing Office.
12. Parman, T., Wiley, M.J., Wells, P.G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999, 5(5): 582-5. (Pubitemid 29220220)
13. D'Amato, R.J., Loughnan, M.S., Flynn, E., Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91(9): 4082-5. (Pubitemid 24139577)
14. Therapontos, C., Erskine, L., Gardner, E.R., Figg, W.D., Vargesson, N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A 2009, 106(21): 8573-8.
15. Knobloch, J., Schmitz, I., Gotz, K., Schulze-Osthoff, K., Ruther, U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 2008, 28(2): 529-38.
16. Sarno, E.N., Grau, G.E., Vieira, L.M., Nery, J.A. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 1991, 84(1): 103-8.
17. Sampaio, E.P., Moreira, A.L., Sarno, E.N., Malta, A.M., Kaplan, G. Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 1992, 175(6): 1729-37.
18. Sampaio, E.P., Kaplan, G., Miranda, A., Nery, J.A., Miguel, C.P., Viana, S.M., Sarno, E.N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993, 168(2): 408-14. (Pubitemid 23210619)
19. Hernandez Mde, O., Fulco Tde, O., Pinheiro, R.O. et al. Thalidomide modulates Mycobacterium leprae-induced NF-kappaB pathway and lower cytokine response. Eur J Pharmacol 2011, 670(1): 272-9.
20. Lee, F.C., Merchant, S.H. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003, 73(1): 48-53. (Pubitemid 36504579)
21. McHugh, S.M., Rifkin, I.R., Deighton, J., Wilson, A.B., Lachmann, P.J., Lockwood, C.M., Ewan, P.W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995, 99(2): 160-7.
22. Verbon, A., Juffermans, N.P., Speelman, P., van Deventer, S.J., ten Berge, I.J., Guchelaar, H.J., van der Poll, T. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother 2000, 44(9): 2286-90. (Pubitemid 30650869)
23. Badamtseren, B., Odkhuu, E., Koide, N. et al. Thalidomide inhibits interferon-gamma-mediated nitric oxide production in mouse vascular endothelial cells. Cell Immunol 2011, 270(1): 19-24.
24. Noman, A.S., Koide, N., Khuda, II et al. Thalidomide inhibits lipopolysaccharide-induced nitric oxide production and prevents lipopolysaccharide-mediated lethality in mice. FEMS Immunol Med Microbiol 2009, 56(3): 204-11.
25. Moller, D.R., Wysocka, M., Greenlee, B.M. et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997, 159(10): 5157-61. (Pubitemid 127471057)
26. Corral, L.G., Muller, G.W., Moreira, A.L., Chen, Y., Wu, M., Stirling, D., Kaplan, G. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996, 2(4): 506-15. (Pubitemid 26271704)
27. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A., Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173(3): 699-703.
28. Tavares, J.L., Wangoo, A., Dilworth, P., Marshall, B., Kotecha, S., Shaw, R.J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med 1997, 91(1): 31-9. (Pubitemid 27105519)
29. Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A., Kaplan, G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993, 177(6): 1675-80. (Pubitemid 23146134)
30. Ye, Q., Chen, B., Tong, Z., Nakamura, S., Sarria, R., Costabel, U., Guzman, J. Thalidomide reduces IL-18, IL-8 and TNFalpha release from alveolar macrophages in interstitial lung disease. Eur Respir J 2006, 28(4): 824-31. (Pubitemid 46335531)
31. Tabata, C., Tabata, R., Kadokawa, Y. et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007, 179(1): 708-14. (Pubitemid 46986590)
32. Choe, J.Y., Jung, H.J., Park, K.Y. et al. Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010, 59(3): 177-88.
33. Zhao, L., Xiao, K., Wang, H. et al. Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies. Clin Exp Immunol 2009, 157(2): 310-5.
34. Tan, H., Chen, H., Xu, C. et al. Role of vascular endothelial growth factor in angiodysplasia: An interventional study with thalidomide. J Gastroenterol Hepatol 2012, 27(6): 1094-101.
35. Andersen, N.F., Vogel, U., Klausen, T.W., Gimsing, P., Gregersen, H., Abildgaard, N., Vangsted, A.J. Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer 2012, 131(5): E636-42.
36. Kenyon, B.M., Browne, F., D'Amato, R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997, 64(6): 971-8. (Pubitemid 27314772)
37. Kim, D., Chung, J. Akt: versatile mediator of cell survival and beyond. J Biochem Mol Biol 2002, 35(1): 106-15. (Pubitemid 35216586)
38. Datta, S.R., Brunet, A., Greenberg, M.E. Cellular survival: a play in three Akts. Genes Dev 1999, 13(22): 2905-27.
39. Brunet, A., Bonni, A., Zigmond, M.J. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96(6): 857-68. (Pubitemid 29165088)
40. Knobloch, J., Shaughnessy, J.D., Jr., Ruther, U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J 2007, 21(7): 1410-21. (Pubitemid 46684844)
41. Leslie, N.R., Downes, C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004, 382(Pt. 1): 1-11. (Pubitemid 39141560)
42. Vacca, A., Ribatti, D., Presta, M. et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999, 93(9): 3064-73. (Pubitemid 29200799)
43. Munshi, N.C., Wilson, C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001, 28(6): 565-9. (Pubitemid 33134415)
44. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F., Dammacco, F. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87(3): 503-8. (Pubitemid 24230014)
45. Barlogie, B., Tricot, G., Anaissie, E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001, 28(6): 577-82. (Pubitemid 33138158)
46. Cavo, M., Pantani, L., Petrucci, M.T. et al. Bortezomib-thalidomide- dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012, 120(1): 9-19.
47. Ho, P.J., Brown, R.D., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D.E. Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leuk Lymphoma 2012, 53(9): 1728-34.
48. Soler, R.A., Howard, M., Brink, N.S., Gibb, D., Tedder, R.S., Nadal, D. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996, 23(3): 501-3.
49. Garcia-Sanz, R., Gonzalez-Lopez, T.J., Vazquez, L., Hermida, G., Graciani, I.F., San Miguel, J.F. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. Eur J Haematol 2010, 84(3): 266-70.
50. Stebbing, J., Benson, C., Eisen, T. et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001, 85(7): 953-8. (Pubitemid 33015995)
51. Kedar, I., Mermershtain, W., Ivgi, H. Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 2004, 110(2): 260-5. (Pubitemid 38580400)
52. Gordon, J.N., Trebble, T.M., Ellis, R.D., Duncan, H.D., Johns, T., Goggin, P.M. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005, 54(4): 540-5. (Pubitemid 40403032)
53. Carlesimo, M., Giustini, S., Rossi, A., Bonaccorsi, P., Calvieri, S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995, 32(5 Pt 2): 866-9.
54. Moller, D.R., Forman, J.D., Liu, M.C. et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996, 156(12): 4952-60. (Pubitemid 26174485)
55. Baughman, R.P., Judson, M.A., Teirstein, A.S., Moller, D.R., Lower, E.E. Thalidomide for chronic sarcoidosis. Chest 2002, 122(1): 227-32. (Pubitemid 34754167)
56. Fazzi, P., Manni, E., Cristofani, R. et al. Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids. Biomed Pharmacother 2012, 66(4): 300-7.
57. Nguyen, Y.T., Dupuy, A., Cordoliani, F., Vignon-Pennamen, M.D., Lebbe, C., Morel, P., Rybojad, M. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 2004, 50(2): 235-41. (Pubitemid 38174281)
58. Lee, J.B., Koblenzer, P.S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998, 39(5 Pt 2): 835-8. (Pubitemid 28520697)
59. Rousseau, L., Beylot-Barry, M., Doutre, M.S., Beylot, C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998, 134(8): 1045-6. (Pubitemid 28385340)
60. Oliver, S.J., Kikuchi, T., Krueger, J.G., Kaplan, G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002, 102(3): 225-36. (Pubitemid 34259256)
61. Yoshizaki, K., Matsuda, T., Nishimoto, N. et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989, 74(4): 1360-7. (Pubitemid 19227448)
62. Beck, J.T., Hsu, S.M., Wijdenes, J. et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994, 330(9): 602-5. (Pubitemid 24065794)
63. Ramasamy, K., Gandhi, S., Tenant-Flowers, M., Ceesay, M., Corderoy, S., Marcus, R., Schey, S. Rituximab and thalidomide combination therapy for Castleman disease. Br J Haematol 2012, 158(3): 421-3.
64. Cuadrado, M.J., Karim, Y., Sanna, G., Smith, E., Khamashta, M.A., Hughes, G.R. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med 2005, 118(3): 246-50. (Pubitemid 40312635)
65. Duong, D.J., Spigel, G.T., Moxley, R.T., 3rd, Gaspari, A.A. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999, 135(9): 1079-87. (Pubitemid 29430499)
66. Housman, T.S., Jorizzo, J.L., McCarty, M.A., Grummer, S.E., Fleischer, A.B., Jr., Sutej, P.G. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003, 139(1): 50-4. (Pubitemid 36091574)
67. Knop, J., Bonsmann, G., Happle, R., Ludolph, A., Matz, D.R., Mifsud, E.J., Macher, E. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983, 108(4): 461-6. (Pubitemid 13116922)
68. Thomson, K.F., Goodfield, M.J. Low-dose thalidomide is an effective second-line treatment in cutaneous lupus erythematosus. J Dermatolog Treat 2001, 12(3): 145-7. (Pubitemid 33116876)
69. Gutierrez-Rodriguez, O., Starusta-Bacal, P., Gutierrez-Montes, O. Treatment of refractory rheumatoid arthritis - the thalidomide experience. J Rheumatol 1989, 16(2): 158-63. (Pubitemid 19085218)
70. Hamuryudan, V., Mat, C., Saip, S. et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128(6): 443-50.
71. Ehrenpreis, E.D., Kane, S.V., Cohen, L.B., Cohen, R.D., Hanauer, S.B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999, 117(6): 1271-7.
72. Vasiliauskas, E.A., Kam, L.Y., Abreu-Martin, M.T. et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999, 117(6): 1278-87.
73. Fernandes, L.B., Guerra, J.G., Costa, M.B., Paiva, I.G., Duran, F.P., Jaco, D.N. Langerhans cells histiocytosis with vulvar involvement and responding to thalidomide therapy - case report. An Bras Dermatol 2011, 86(4, Suppl. 1): S78-81.
74. Miller, S., Sharda, S., Rodrigue, J., Mehta, P. Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life. Int J Hematol 2002, 76(4): 365-9. (Pubitemid 43014102)
75. Saurat, J.H., Camenzind, M., Helg, C., Chapuis, B. Thalidomide for graft-versus-host disease after bone marrow transplantation. Lancet 1988, 1(8581): 359.
76. van de Poel, M.H., Pasman, P.C., Schouten, H.C. The use of thalidomide in chronic refractory graft versus host disease. Neth J Med 2001, 59(2): 45-9.
77. Jacobson, J.M., Greenspan, J.S., Spritzler, J. et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997, 336(21): 1487-93. (Pubitemid 27215163)
78. Katzenstein, A.L. Idiopathic interstitial pneumonia: classification and diagnosis. Monogr Pathol 1993, 36: 1-31.
79. Raghu, G., Collard, H.R., Egan, J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6): 788-824.
80. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161(2, Pt. 1): 646-64.
81. Katzenstein, A.L., Myers, J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157(4, Pt. 1): 1301-15.
82. Johnston, I.D., Prescott, R.J., Chalmers, J.C., Rudd, R.M. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997, 52(1): 38-44. (Pubitemid 27047223)
83. Coultas, D.B., Zumwalt, R.E., Black, W.C., Sobonya, R.E. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994, 150(4): 967-72. (Pubitemid 24318021)
84. King, T.E., Jr., Tooze, J.A., Schwarz, M.I., Brown, K.R., Cherniack, R.M. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 2001, 164(7): 1171-81. (Pubitemid 33052246)
85. King, T.E., Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 2005, 172(3): 268-79.
86. King, T.E., Jr., Schwarz, M.I., Brown, K. et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001, 164(6): 1025-32. (Pubitemid 32971653)
87. Raghu, G., Brown, K.K. Interstitial lung disease: clinical evaluation and keys to an accurate diagnosis. Clin Chest Med 2004, 25(3): 409-19, v. (Pubitemid 39149794)
88. Raghu, G., Chang, J. Idiopathic pulmonary fibrosis: current trends in management. Clin Chest Med 2004, 25(4): 621-36, v. (Pubitemid 39561702)
89. Borchers, A.T., Chang, C., Keen, C.L., Gershwin, M.E. Idiopathic pulmonary fibrosis-an epidemiological and pathological review. Clin Rev Allergy Immunol 2011, 40(2): 117-34.
90. Selman, M., King, T.E., Pardo, A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001, 134(2): 136-51. (Pubitemid 32096342)
91. King, T.E., Jr., Pardo, A., Selman, M. Idiopathic pulmonary fibrosis. Lancet 2011, 378(9807): 1949-61.
92. Hardie, W.D., Bruno, M.D., Huelsman, K.M. et al. Postnatal lung function and morphology in transgenic mice expressing transforming growth factor-alpha. Am J Pathol 1997, 151(4): 1075-83. (Pubitemid 27424317)
93. Hardie, W.D., Le Cras, T.D., Jiang, K., Tichelaar, J.W., Azhar, M., Korfhagen, T.R. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2004, 286(4): L741-9. (Pubitemid 38365059)
94. Hardie, W.D., Davidson, C., Ikegami, M. et al. EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008, 294(6): L1217-25.
95. Selman, M., Pardo, A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006, 3(4): 364-72. (Pubitemid 43845414)
96. Sime, P.J., O'Reilly, K.M. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001, 99(3): 308-19.
97. Korfei, M., Ruppert, C., Mahavadi, P. et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 178(8): 838-46.
98. Xia, H., Diebold, D., Nho, R. et al. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 2008, 205(7): 1659-72. (Pubitemid 351962029)
99. Selman, M., Pardo, A., Kaminski, N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008, 5(3): e62.
100. White, E.S., Atrasz, R.G., Hu, B. et al. Negative regulation of myofibroblast differentiation by PTEN (Phosphatase and Tensin Homolog Deleted on chromosome 10). Am J Respir Crit Care Med 2006, 173(1): 112-21. (Pubitemid 43069796)
101. Moodley, Y.P., Caterina, P., Scaffidi, A.K. et al. Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasLinduced apoptosis. J Pathol 2004, 202(4): 486-95. (Pubitemid 38456167)
102. Moodley, Y.P., Misso, N.L., Scaffidi, A.K. et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 2003, 29(4): 490-8. (Pubitemid 37222687)
103. Buhling, F., Wille, A., Rocken, C. et al. Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis. Respir Res 2005, 6: 37.
104. Raghu, G., Brown, K.K., Costabel, U. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008, 178(9): 948-55.
105. Raghu, G., Brown, K.K., Bradford, W.Z., Starko, K., Noble, P.W., Schwartz, D.A., King, T.E., Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004, 350(2): 125-33. (Pubitemid 38056223)
106. Daniels, C.E., Lasky, J.A., Limper, A.H., Mieras, K., Gabor, E., Schroeder, D.R. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010, 181(6): 604-10.
107. Noble, P.W., Albera, C., Bradford, W.Z. et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377(9779): 1760-9.
108. Taniguchi, H., Ebina, M., Kondoh, Y. et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35(4): 821-9.
109. Keane, M.P., Arenberg, D.A., Lynch, J.P., 3rd et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997, 159(3): 1437-43. (Pubitemid 127484123)
110. Ebina, M., Shimizukawa, M., Shibata, N. et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004, 169(11): 1203-8. (Pubitemid 38680397)
111. Zisman, D.A., Schwarz, M., Anstrom, K.J., Collard, H.R., Flaherty, K.R., Hunninghake, G.W. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363(7): 620-8.
112. Raghu, G., King, T.E., Jr., Behr, J. et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010, 35(1): 118-23.
113. Horton, M.R., Danoff, S.K., Lechtzin, N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax 2008, 63(8): 749.
114. Horton, M.R., Santopietro, V., Mathew, L. et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med 2012, 157(6): 398-406.
115. Hope-Gill, B.D., Hilldrup, S., Davies, C., Newton, R.P., Harrison, N.K. A study of the cough reflex in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168(8): 995-1002. (Pubitemid 37267179)
116. Brown, K.K. Chronic cough due to chronic interstitial pulmonary diseases: ACCP evidence-based clinical practice guidelines. Chest 2006, 129(1, Suppl.): 180S-5S. (Pubitemid 43273176)
117. Ryerson, C.J., Abbritti, M., Ley, B., Elicker, B.M., Jones, K.D., Collard, H.R. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 2011, 16(6): 969-75.
118. Madison, J.M., Irwin, R.S. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med 2005, 11(5): 412-6. (Pubitemid 41291085)
119. Chung, K.F., Pavord, I.D. Prevalence, pathogenesis, and causes of chronic cough. Lancet 2008, 371(9621): 1364-74. (Pubitemid 351540823)
120. Harrison, N.K. Idiopathic pulmonary fibrosis: a nervous cough? Pulm Pharmacol Ther 2004, 17(6): 347-50. (Pubitemid 39572474)
121. Doherty, M.J., Mister, R., Pearson, M.G., Calverley, P.M. Capsaicin induced cough in cryptogenic fibrosing alveolitis. Thorax 2000, 55(12): 1028-32.
122. Antonioli, E., Nozzoli, C., Gianfaldoni, G. et al. Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. Ann Oncol 2005, 16(11): 1849-50. (Pubitemid 41631255)
123. Hattori, Y., Shimoda, M., Okamoto, S., Satoh, T., Kakimoto, T., Ikeda, Y. Pulmonary hypertension and thalidomide therapy in multiple myeloma. Br J Haematol 2005, 128(6): 885-7. (Pubitemid 40444885)
124. Younis, T.H., Alam, A., Paplham, P., Spangenthal, E., McCarthy, P. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma. Br J Haematol 2003, 121(1): 191-2. (Pubitemid 36461290)
125. Lafaras, C., Mandala, E., Verrou, E., Platogiannis, D., Barbetakis, N., Bischiniotis, T., Zervas, K. Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study. Ann Oncol 2008, 19(10): 1765-9.
126. Villa, A., Mazzola, A.A., Ghio, S., Martinoli, E., Marino, P. Reversible pulmonary hypertension related to thalidomide treatment for multiple myeloma. Case Rep Oncol 2011, 4(3): 487-9.
127. Kang, M.H., Ju, J.H., Kim, H.G., Kang, J.H., Jeon, K.N., Kim, H.C., Lee, G.W. Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma. Korean J Intern Med 2010, 25(4): 447-9.
128. Tilluckdharry, L., Dean, R., Farver, C., Ahmad, M. Thalidomide-related eosinophilic Pneumonia: A case report and brief literature review. Cases J 2008, 1(1): 143.
129. Chaudhry, V., Cornblath, D.R., Corse, A., Freimer, M., Simmons-O'Brien, E., Vogelsang, G. Thalidomide-induced neuropathy. Neurology 2002, 59(12): 1872-5. (Pubitemid 36076557)
130. Bowcock, S.J., Rassam, S.M., Ward, S.M., Turner, J.T., Laffan, M. Thromboembolism in patients on thalidomide for myeloma. Hematology 2002, 7(1): 51-3. (Pubitemid 34692987)
131. Tseng, S., Pak, G., Washenik, K., Pomeranz, M.K., Shupack, J.L. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996, 35(6): 969-79. (Pubitemid 26422122)